Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Comparison of brolucizumab and aflibercept for treating DME
A study found brolucizumab non-inferior to aflibercept in treating DME, with superior anatomic outcomes. Both drugs showed similar adverse event rates. The meta-analysis underscores the need for further trials to assess safety outcomes for brolucizumab as a DME treatment alternative.
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following
Regeneron announced positive Phase 2 results for REGN7508 (catalytic domain) and REGN9933 (A2 domain), showing robust antithrombotic effects with minimal bleeding risk after single doses. The Phase 3 program is set to begin in 2025.
Regeneron Will Move Two Factor XI Agents Into Phase III
Regeneron plans to move two factor XI agents, REGN7508 and REGN9933, into Phase III after successful Phase II data versus active comparators, aiming to compete against existing factor X products.
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following ...
REGN7508 (catalytic domain) and REGN9933 (A2 domain) show robust antithrombotic effects with minimal bleeding risk in Phase 2 trials post total knee replacement. Phase 3 program to start in 2025.
Regeneron to Advance Two Factor XI Antibodies into a Broad
REGN7508 (catalytic domain) and REGN9933 (A2 domain) show robust antithrombotic effects with minimal bleeding risk in Phase 2 trials post-knee replacement. Both antibodies demonstrated non-inferiority to current standards of care, with REGN7508 showing superiority to enoxaparin. No major bleeding incidents were reported. A Phase 3 program is planned for 2025.
© Copyright 2024. All Rights Reserved by MedPath